Ace­sion clinch­es $47M in Se­ries B raise to ad­vance pre­clin­i­cal car­diac ar­rhyth­mia can­di­date through PhII

Ace­sion Phar­ma has bagged 45 mil­lion eu­ros ($47 mil­lion) in an over­sub­scribed Se­ries B round. The fund­ing will sup­port its pre­clin­i­cal oral potas­si­um chan­nel in­hibitor for the pre­ven­tion of atri­al fib­ril­la­tion (AF) re­cur­rence through Phase II.

The Se­ries B was co-led by new US-based back­ers Canaan and Al­pha Wave, with sup­port from Glob­al BioAc­cess Fund and ex­ist­ing in­vestor No­vo Hold­ings.

The funds will be used to ad­vance Copen­hagen-based Ace­sion’s potas­si­um chan­nel in­hibitor for the chron­ic main­te­nance treat­ment of AF, dubbed AP31969, in­to the clin­ic and to the end of Phase II de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER